Vicarious Surgical INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Vicarious Surgical Inc. reported a net loss of $7.3 million for the first quarter of 2026, a significant reduction from the prior year's $15.4 million loss, driven by substantial decreases in operating expenses.
OQB
Vicarious Surgical Inc. reported a reduced net loss for Q3 2025, but faces substantial doubt about its ability to continue as a going concern despite a recent $5.2 million capital raise.
OQB
Vicarious Surgical reported continued net losses and significant doubt about its ability to continue as a going concern, while addressing NYSE listing non-compliance.
OQB
10-Q: Vicarious Surgical Reports Q1 2025 Results Amidst NYSE Listing Concerns and Ongoing Development
Vicarious Surgical faces NYSE compliance issues and continues product development with a net loss of $15.39 million for Q1 2025.
OQB
Vicarious Surgical reported a net loss of $17.1 million for the third quarter of 2024, an improvement compared to the $15.7 million loss in the same period last year, driven by reduced operating expenses.
OQB
Vicarious Surgical's Q2 2024 results show a reduced net loss compared to the same period last year, driven by lower operating expenses.
OQB
Vicarious Surgical files an amendment to its Q1 2024 report to correct the number of Class A common shares outstanding.
OQB
Vicarious Surgical reported a reduced net loss for the first quarter of 2024, driven by lower operating expenses, despite remaining pre-revenue.